公开(公告)号：US20240050523A1

公开(公告)日：2024-02-15

申请号：US18447152

申请日：2023-08-09

Applicant: SHIFTBIO INC. ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi-Hoon NAM ,  Gi Beom KIM ,  Jae Hyun KIM ,  Yeji LEE ,  Jiyoung GOO ,  Seongeun CHO ,  Cherlhyun JEONG ,  In-San KIM

IPC: A61K38/17 ,  A61K9/127 ,  A61K47/65 ,  A61P1/16 ,  A61P29/00 ,  A61K47/69 ,  A61K47/64

CPC classification number: A61K38/1709 ,  A61K9/127 ,  A61K38/177 ,  A61K47/65 ,  A61P1/16 ,  A61P29/00 ,  A61K47/6911 ,  A61K47/64

Abstract: The present invention generally relates to an extracellular vesicle (EV) comprising a subunit of a heterodimeric transcription factor, an EV polypeptide, and a monomeric cis-cleaving intein and a method of using the EV.

公开(公告)号：US12295978B2

公开(公告)日：2025-05-13

申请号：US16967074

申请日：2018-09-28

Applicant: SHIFTBIO INC.

Inventor： Gi-Beom Kim ,  Yoo Soo Yang ,  In-San Kim ,  Gihoon Nam

IPC: A61K35/766 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162nd amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.

公开(公告)号：US20240209063A1

公开(公告)日：2024-06-27

申请号：US18596778

申请日：2024-03-06

Applicant: SHIFTBIO INC.

Inventor： Eun-ee KOH ,  Eun Jung LEE ,  Yoo Soo YANG ,  In-San KIM

IPC: C07K14/71 ,  A61K38/00 ,  A61P35/00 ,  C12N9/12

CPC classification number: C07K14/71 ,  A61P35/00 ,  C12N9/12 ,  C12Y207/10001 ,  A61K38/00 ,  C07K2319/03

Abstract: The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface of the exosome.

公开(公告)号：US20240024418A1

公开(公告)日：2024-01-25

申请号：US18357160

申请日：2023-07-24

Applicant: SHIFTBIO INC.

Inventor： Gi-Hoon NAM ,  Gi Beom KIM ,  Seohyun KIM ,  Yoon Kyoung KIM ,  Jae Hyun KIM ,  Seonghyun KIM

IPC: A61K38/17 ,  C12N5/0775 ,  C12N15/86 ,  A61K47/69 ,  A61P29/00 ,  A61P1/16

CPC classification number: A61K38/1774 ,  C12N5/0663 ,  C12N15/86 ,  A61K47/6901 ,  A61P29/00 ,  A61P1/16 ,  C12N2510/02 ,  C12N2740/15043

Abstract: The present invention generally relates to a stem cell-derived extracellular vesicle (EV) comprising a signal regulatory protein (SIRP) and a method for preventing or treating cancer and/or inflammatory disease, condition, or symptom by using the stem cell-derived EV.

公开(公告)号：US20230381226A1

公开(公告)日：2023-11-30

申请号：US18322723

申请日：2023-05-24

Applicant: SHIFTBIO INC. ,  Korea Institute of Science and Technology

Inventor： In San KIM ,  Seungyoon PARK ,  Gi-Hoon NAM ,  Inkyu LEE

IPC: A61K35/12 ,  C12N15/85 ,  C12N5/00

CPC classification number: A61K35/12 ,  C12N15/85 ,  C12N5/0006 ,  C12N2800/107

Abstract: The present invention provides surface-engineered extracelluar vesicles, compositions comprising the surface-engineered extracelluar vesicles, methods for preparing the surface-engineered extracelluar vesicles, and methods for using the surface-engineered extracelluar vesicles or the compositions.